Find the best CNRS technologies to boost your innovative project.
06.11.2018
Materials – Coating 07293-01
06.11.2018
Materials – Coating 10581-01
06.11.2018
Chemistry / Environment 08758-01
06.11.2018
11127-01
06.11.2018
Environment and Energy 11107-01
19.10.2018
Medical Diagnostic 08504-01
We can guide you through the whole technology transfer process.
Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.
09443-0109443-02
EPT 15306556 and EP 153065552 filed 2/10/2015
Yoann Menon
Christophe Long
Ludovic Halby
EB Kaloum
François Sautel
Paola B. Arimondo
Exclusive or non-exclusive licenses
ETaC CNRS
Epigenetic modifications play an essential role in the establishment and regulation of differentiation programs that define when and where genes are expressed. Among these modifications, C5 methylation of deoxycytidines (dC) in the DNA was shown to play a key role in the epigenetic regulation in mammals. The C5 DNA methyltransferases, DNMT, are responsible for DNA methylation Alterations of DNA methylation patterns lead to various diseases such as cancer and neurological diseases. Cancerous cells present aberrant DNA methylation, in particular a specific hypermethylation of tumour suppressor genes is observed inducing their silencing. Restoring their expression by specific inhibition of DNA methylation represents an attractive therapeutic strategy. In addition it has been shown that demethylating agents prime cancer cells towards immunotherapy and sensitize them towards chemotherapy.
Bisbenzylisoquinoline alkaloids and hemisynthetic derivatives developed in this invention can be used as DNMT inhibitors.
The compounds
Ø inhibit the DNMT3A in the micromolar level (0.6µM)
Ø demethylate gene promoters and induce gene expression in cancer cells
Ø induce chromatin opening
Ø reduce certain tumor phenotype of cancer cells
The compounds are able to inhibit DNA methylation in enzymatic assays, and to demethylate and reactivate genes when used at low doses for prolonged treatments.
The main application is as drugs for cancer treatment, mainly in combination with other epigenetic drugs or chemotherapy or immune-therapy
For further information, please contact us (Ref 09443-01 / 09443-02)
08.02.2017
Chemistry / Environment, Health / Therapeutic, Medical Diagnostic, Materials – Coating 00957-03
04.06.2015
Health / Therapeutic 02147-01
09.03.2015
Health / Therapeutic, Medical Diagnostic 04009-01
06.11.2018
Materials – Coating 07293-01
06.11.2018
Materials – Coating 10581-01
06.11.2018
Chemistry / Environment 08758-01
06.11.2018
11127-01
06.11.2018
Environment and Energy 11107-01
19.10.2018
Medical Diagnostic 08504-01